Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
McKesson
Express Scripts
Merck
Baxter

Last Updated: March 29, 2023

Glenmark Specialty Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for GLENMARK SPECIALTY, and when can generic versions of GLENMARK SPECIALTY drugs launch?

GLENMARK SPECIALTY has one approved drug.

There are thirteen US patents protecting GLENMARK SPECIALTY drugs.

There are seventy patent family members on GLENMARK SPECIALTY drugs in thirty countries and eight supplementary protection certificates in seven countries.

Summary for Glenmark Specialty
International Patents:70
US Patents:13
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Glenmark Specialty

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 10,016,443 See Plans and Pricing See Plans and Pricing
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 10,646,500 See Plans and Pricing See Plans and Pricing
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 10,758,550 See Plans and Pricing See Plans and Pricing
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 11,400,101 See Plans and Pricing See Plans and Pricing
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 9,750,754 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Glenmark Specialty Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 132021000000191 Italy See Plans and Pricing PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426
3043773 CA 2021 00050 Denmark See Plans and Pricing PRODUCT NAME: MOMETASON ELLER ET SALT DERAF OG OLOPATADIN ELLER ET SALT DERAF; NAT. REG. NO/DATE: 63820 20210706; FIRST REG. NO/DATE: AT 140638 20210426
0548114 SPC/GB97/064 United Kingdom See Plans and Pricing PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
3043773 122021000085 Germany See Plans and Pricing PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; NAT. REGISTRATION NO/DATE: 2205824.00.00 20211117; FIRST REGISTRATION: OESTERREICH 140638 20210426
3043773 2022C/520 Belgium See Plans and Pricing PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
Johnson and Johnson
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.